Prostate Cancer Gene 3 and Multiparametric Magnetic Resonance Can Reduce Unnecessary Biopsies: Decision Curve Analysis to Evaluate Predictive Models

Heidenreich, 2011, EAU guidelines on prostate cancer. European Association of Urology, Eur Urol, 52, 68 Sardana, 2008, Emerging biomarkers for the diagnosis and prognosis of prostate cancer, Clin Chem, 54, 1951, 10.1373/clinchem.2008.110668 Auprich, 2011, Contemporary role of prostate cancer antigen 3 in the management of prostate cancer, Eur Urol, 60, 1045, 10.1016/j.eururo.2011.08.003 Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014 Goode, 2013, Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients, Prostate, 73, 48, 10.1002/pros.22538 Ruiz-Aragón, 2010, Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis, Actas Urol Esp, 34, 346, 10.1016/j.acuro.2010.02.019 Chun, 2010, Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature, Eur Urol, 58, 851, 10.1016/j.eururo.2010.08.041 Wang, 2009, Rational approach to implementation of prostate cancer antigen 3 into clinical care, Cancer, 115, 3879, 10.1002/cncr.24447 Kirby, 2012, Optimising repeat prostate biopsy decisions and procedures, BJU Int, 109, 1750, 10.1111/j.1464-410X.2011.10809.x Sciarra, 2011, Advances in magnetic resonance imaging: how they are changing the management of prostate cancer, Eur Urol, 59, 962, 10.1016/j.eururo.2011.02.034 Sciarra, 2010, Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy, Clin Cancer Res, 16, 1875, 10.1158/1078-0432.CCR-09-2195 Sciarra, 2012, Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy, BJU Int, 110, 1661, 10.1111/j.1464-410X.2012.11146.x Sciarra, 2008, Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates, Urol Int, 80, 145, 10.1159/000112604 Hessels, 2003, DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X Deras, 2008, PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 179, 1587 Lawrentschuk, 2008, The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate specific antigen levels, BJU Int, 103, 730, 10.1111/j.1464-410X.2008.08205.x DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making, 26, 565, 10.1177/0272989X06295361 Yang, 2010, Improvements in ability to detect undiagnosed diabetes by using information on family history among adults in the United States, Am J Epidemiol, 171, 1079, 10.1093/aje/kwq026 Vickers, 2010, Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication, J Clin Oncol, 28, 2493, 10.1200/JCO.2009.24.1968 Roobol, 2010, Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100), Eur Urol, 58, 893, 10.1016/j.eururo.2010.09.030 Salagierski, 2012, Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion, J Urol, 187, 795 Chun, 2009, Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram, Eur Urol, 56, 659, 10.1016/j.eururo.2009.03.029 Auprich, 2010, External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome, Eur Urol, 58, 727, 10.1016/j.eururo.2010.06.038 Perdonà, 2011, Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3, Eur Urol, 59, 81, 10.1016/j.eururo.2010.09.036 Pepe, 2011, PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy, Anticancer Res, 31, 4445 Moore, 2013, Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review, Eur Urol, 63, 125, 10.1016/j.eururo.2012.06.004 Schröder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084